

20 September 2022

Treatment of Cervical and Endometrial Cancer

1. Does your Trust provide SACT (Systemic Anti-Cancer Therapy) treatments for the following conditions?

- Cervical cancer Yes
- Endometrial cancer Yes

2. How many patients were treated for cervical cancer in the past 6 months with the following treatments?

- Paclitaxel in combination with Platinum and/or Bevacizumab <5
- Pembrolizumab in combination with Platinum and/or Bevacizumab <5
- Platinum standalone or in combination with Bevacizumab 22
- Topotecan in combination with Platinum and/or Bevacizumab <5
- Any other SACT:
 - Etoposide + Cisplatin <5
 - Paclitaxel Weekly <5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

3. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:

- Dostarlimab <5
- Hormone therapy (Progesterone or Letrozole) <5
- Pembrolizumab in combination with Lenvatinib <5
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) 66
- Any other SACT: Paclitaxel Weekly 7

4. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:

- Hormone therapy (Progesterone or Letrozole) <5
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) 31
- Any other SACT <5

20 September 2022

5. **Does your Trust participate in any clinical trials for the treatment of cervical cancer? If so, can you please provide the name of each trial and the number of patients taking part?**

INTERLACE	A phase III multi-centre trial of weekly induction chemotherapy followed by standard chemo-radiation versus standard chemo-radiation alone in patients with locally advanced cervical cancer	13 patients recruited
------------------	--	-----------------------

RaNGO	Rare Neoplasms of Gynaecological Origin (this study includes cervical cancer patients)	31 patients recruited
--------------	--	-----------------------

6. **Does your Trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part?**

There are no active trials in endometrial cancer at present, although we have had trials in this area in the past.